MedTrace Logo

-Oleoyl Glycerol is a GPR119 Agonist and Signals GLP-1 Release in Humans.

NCT01043445 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2014-10-09

No results posted yet for this study

Summary

The purpose of this study is to evaluate the impact of different ligands of GPR 119 (a G protein-coupled receptor in the intestine) on the secretion of the incretin hormones, GLP-1 and GIP.

Conditions

Interventions

DIETARY_SUPPLEMENT

GPR 119 agonist, 2-oleyl glycerol

Emulgation, 50 ml. containing 2g 2OG

DIETARY_SUPPLEMENT

Oleic acid

Emulgation, 50 ml. containing 1.54g of oleic acid

DIETARY_SUPPLEMENT

Vehicle

Fifty milliliters of glycerol (Sigma-Aldrich; batch 32296AK, purity 99%) plus 5 ml 96% ethanol

Sponsors & Collaborators

  • University of Copenhagen

    collaborator OTHER

  • Glostrup University Hospital, Copenhagen

    lead OTHER

Principal Investigators

  • Katrine B Hansen, MD · Glostrup Hospital, University of Copenhagen

  • Filip K Knop, MD, Ph.d · Gentofte Hospital

  • Harald S Hansen, professor · Farmaceutical Faculty, University of Copenhagen

  • Jens J Holst, MD;DMSc · Biomedical Science, University of Copenhagen

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2010-03-31
Completion
2010-04-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01043445 on ClinicalTrials.gov